Birinapant
Birinapant has been studied in 2 papers since 2025: 1 observational study in people, 1 in animals; 1 in the past year. The newest paper, May 4, 2026: “Co-morbid biomarkers for sarcopenic obesity associated with gut microbiota metabolites: From burden to treatment”.
See all 2 papers on birinapant
At a glance
The findings reach mice, none yet in people. 1 lab in 1 country; 4 trials, none about aging, 3 with no results posted.
- 1 lab in 1 country
- 4 trials, none about aging, 3 with no results posted
- Funders: American Cancer Society and 7 more
- Humans1
- Animals1
What did studies of birinapant find?
1Studies of birinapant measured one outcome, glioblastoma.
Glioblastoma
downin mice1
1 study
Glioblastoma
downin mice1
Birinapant prevents glioblastoma in mice (as an adjuvant after radiotherapy in PDX and immunocompetent mouse models of GBM).
Animalsas an adjuvant after radiotherapy in PDX and immunocompetent mouse models of GBM
Trial sponsors
Company2 trialsPhase 2139 people
Company1 trialPhase 1272 people
1 trialPhase 113 people